Clinical trials: Renal Allograft
Chronic Allograft Dysfunction in Renal Transplantation
Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients
Despite the remarkable improvement in short-term patient and graft survival among the recipients of kidney transplants, the progressive renal dysfunction (chronic allograft dysfunction) accompanied by chronic interstitial…
- Trial name
- NCT01046045
- Testing
- everolimus
- Where
- Hong Kong
- Volunteers
- 17 people
- Sponsor
- Chinese University of Hong Kong
Graft Rejection, Kidney Transplantation
Artificial Intelligence Model for Renal Allograft Rejection Identification, Lesion Quantification and Rejection Risk Prediction Based on Prospective Renal Transplant Pathology and Clinical Multidimensional Data
This prospective research collects leftover kidney biopsy tissue slides and matching routine clinical data from patients who received kidney transplants and underwent standard kidney puncture biopsy at Zhejiang University School…
- Conditions
- Graft Rejection, Kidney Transplantation, Glomerulonephritis, Polyomavirus Infections
- Trial name
- NCT07741552
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chen Dajin
Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
A multicenter clinical study comparing event-free survival at 6 months after transplant between Thymoglobulin-treated and Simulect-treated adult kidney transplant patients.
- Conditions
- Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection, Induction Therapy
- Trial name
- NCT00235300
- Testing
- Thymoglobulin [Anti-thymocyte Globulin (rabbit)], Simulect (basliximab)
- Where
- 28 sites in United States, France and 3 more
- Volunteers
- 240 people
- Sponsor
- Genzyme, a Sanofi Company
Renal Failure
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
This study will evaluate the efficacy and safety of LCP-Tacro (tacrolimus) Tablets administered once-a-day compared to Prograf (tacrolimus) Capsules twice-a-day as immunosuppression for the prevention of organ rejection in newly…
- Trial name
- LCPTacro3002 (NCT01187953)
- Testing
- Prograf (tacrolimus), LCP-Tacro
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 543 people
- Sponsor
- Veloxis Pharmaceuticals
Kidney Transplantation
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection.
- Trial name
- NCT00483756
- Testing
- Cyclosporine, CP-690,550
- Where
- 69 sites in United States, Australia and 13 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Late Complication From Kidney Transplant
Tocilizumab for Renal Graft Inflammation
Randomized open label clinical trial in which 48 renal transplant recipients with inflammation in the 6 month allograft biopsy will either continue usual immunosuppression or receive monthly Actemra (Tocilizumab) infusions for 6…
- Trial name
- NCT02108600
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Flavio Vincenti
Renal Transplant Recipients
Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk
To compare renal function (51Cr-EDTA clearance) 12 months posttransplant, in primary renal allograft recipients (from cadaveric donor) at low immunogenic risk, 0 DR mis-match, receiving immunosuppressive therapy with A) Zenapax®…
- Trial name
- NCT00138970
- Testing
- Zenapax®, CellCept® and prednisolone, Sandimmun Neoral®, CellCept® and prednisolone
- Volunteers
- 70 people
- Sponsor
- University of Oslo School of Pharmacy
End Stage Renal Disease, Kidney Failure
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
The use of C1INH (Berinert) in patients receiving deceased donor kidney transplants with high risk for delayed graft function (DGF) may show significant improvement in outcomes post transplant compared with patients that do not…
- Conditions
- End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
- Trial name
- C1INHDGF (NCT02134314)
- Testing
- C1 Esterase Inhibitor
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Cedars-Sinai Medical Center
Liver Transplant
A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.
Assuming greater efficacy in the prevention of acute rejection in the EVR arm with minimisation of TAC levels, the hypothesis of the present trial was that the introduction of EVR in combination with the minimisation of TAC…
- Trial name
- REDUCE (NCT02040584)
- Testing
- Minimisation of TAC, TAC + MMF + corticosteroids
- Where
- 20 sites in Spain
- Volunteers
- 217 people
- Sponsor
- Novartis Pharmaceuticals
Renal Transplant Rejection
Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes
The goal of this observational study is to determine phenotypic, transcriptional, and epigenetic underpinnings of renal allograft rejection in renal transplant rejection.
- Trial name
- NCT06438107
- Where
- United States
- Sponsor
- University of Pittsburgh
Kidney Transplantation
Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
The aim of this trial is to compare the safety and efficacy of a single dose of Thymoglobulin, rabbit derived antithymocyte globulin (Thymoglobulin, SangStat, Fremont, CA) to our standard four dose, four day Thymoglobulin…
- Trial name
- NCT00235781
- Testing
- Thymoglobulin
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Washington University School of Medicine
Kidney Transplantation, Diabetes Mellitus, Type 2
EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce plasma glucose and haemoglobin A1c(HbA1c) in patients with type 2 diabetes mellitus by increasing urinary glucose excretion in a non-insulin-dependent fashion.
- Conditions
- Kidney Transplantation, Diabetes Mellitus, Type 2, Diabetes Complications
- Trial name
- NCT04743453
- Testing
- Dapagliflozin
- Where
- Brazil
- Volunteers
- 211 people
- Sponsor
- University of Sao Paulo General Hospital
Renal Transplant Rejection, Immunosuppression
Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant
Currently, acute kidney injury is diagnosed by increased serum creatinine. However, creatinine is not a reliable marker for acute changes in renal function.
- Trial name
- NCT01239472
- Testing
- Everolimus
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Andre Barreto Pereira
Kidney Transplantation
Predictors and Intervention for Noncompliance
This is a randomized controlled intervention trial in poorly compliant patients, testing whether improved compliance behavior decreases rates of acute rejection risk and graft loss.
- Trial name
- NCT00148174
- Testing
- Intensive telephone followup
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- University of Minnesota
Transplantation, Kidney
The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.
- Trial name
- NCT00617474
- Testing
- Erythropoietin
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Labbafinejhad Hospital
Organ Transplantation
Mesenchymal Stem Cells and Subclinical Rejection
The purpose of the study is to test the safety and feasibility of autologous mesenchymal stem cell therapy in HLA-DR mismatched patients with subclinical rejection and or an increase in IF?TA in the renal biopsy 4 weeks or 6…
- Trial name
- Measure (NCT00734396)
- Testing
- Mesenchymal stem cell infusion
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Leiden University Medical Center
Kidney Transplantation
Noninvasive Evaluation of Renal Allograft Fibrosis by MRI
The purpose of this study is to validate an MRI method to detect renal fibrosis in patients after kidney transplantation (KT).
- Trial name
- NCT04899167
- Testing
- MRI 1.5T and 3.0T
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Mayo Clinic
Kidney Failure
Resistive Index Measurements After Kidney Transplantation
The purpose of this study is to evaluate the prognostic performance of intrarenal resistive index in the first years after kidney transplantation on graft function and on patient and graft survival.
- Trial name
- NCT01879124
- Where
- Belgium
- Volunteers
- 346 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Kidney Transplant, Renal Transplant
Predictive Accuracy of Machine Perfusion for Kidney Transplant Outcomes in Germany
Kidney transplantation remains the only definitive treatment for end-stage renal disease, yet the increasing use of extended criteria donor (ECD) kidneys heightens the risk of ischemia-reperfusion injury, particularly under…
- Conditions
- Kidney Transplant, Renal Transplant, Organ Preservation
- Trial name
- PRE-MAP-Kidney (NCT07348874)
- Volunteers
- 300 people
- Sponsor
- University Hospital Heidelberg
Kidney Transplant, Renal Allograft Recipients
A Mixed Cohort, Multicentre Exploratory Study of Non-invasive Quantitative Assessment of Renal Graft Function With Non-contrast Functional Magnetic Resonance Imaging
This clinical study aims to investigate a new, non-invasive method for monitoring kidney function after transplantation. Currently, assessing the health of a transplanted kidney often relies on blood tests or invasive biopsies…
- Conditions
- Kidney Transplant, Renal Allograft Recipients, Renal Allograft
- Trial name
- NCT07333495
- Where
- 3 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Tongji Hospital